Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab.

Korean J Intern Med

Department of Internal Medicine, The Catholic University of Korea, College of Medicine, 520-2 Daeheung-dong, Jung-gu, Daejeon, Korea.

Published: September 2008

Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686964PMC
http://dx.doi.org/10.3904/kjim.2008.23.3.156DOI Listing

Publication Analysis

Top Keywords

iib/iiia inhibitors
12
hemorrhagic pericarditis
8
pericarditis cardiac
8
cardiac tamponade
8
percutaneous coronary
8
coronary intervention
8
associated abciximab
8
myocardial infarction
8
risks associated
8
tamponade percutaneous
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!